Table 5.
Discordant Trunk Driver Mutations Between Primary and Metastatic Lung Cancer Specimens
| Pairsa | Tumor %b | Trunk Driver Mutations | TP53 |
|---|---|---|---|
| PM03 | |||
| LN, 4R (FNA) | 11-30 | NMD (3/1158 reads)c | NMD |
| RUL (Re: ypT2bypN1, 6 m) | 21-40 | KRAS p.A146V (12%) | NMD |
| PM10 | |||
| LN,11R (FNA) | 61-80 | EGFR p.E746_A750del (65%) | NMD |
| LUL (Re: T1aNx, 1 m) | 41-60 | KRAS p.G13D (46%) | p.R280K (23%) |
| p.N131S (6.0%) | |||
| PM26 | |||
| RML (Re: T1aN0) | 31-50 | BRAF p.V600E (16%) | NMD |
| Brain (Re, 24 m) | 61-80 | NMD (0/1272 reads) | p.R158P (27%) |
11R, right interlobar; FNA, fine-needle aspiration; 4R, right lower paratracheal; LN, lymph node; LUL, left upper lobe; NMD, no mutation detected; Re, resection; RML, right middle lobe; RUL, right upper lobe.
aNumber of months (m) in parentheses indicates duration after the first specimens were taken.
bTumor % is estimated tumor cellularity.
cBelow the limit of detection of the next-generation sequencing assay (3/1,158 = 0.3%).